Daniel P Petrylak
Metastatic Hormone-Sensitive Prostate Cancer: Clinical Decision Making in a Rapidly Evolving Landscape of Life-Prolonging Therapy
VanderWeele D, Sweeney C, Petrylak D, Morgans A, Higano C, Gillessen Sommer S, Fizazi K, Dreicer R, Carducci M, Antonarakis E, Hussain M. Metastatic Hormone-Sensitive Prostate Cancer: Clinical Decision Making in a Rapidly Evolving Landscape of Life-Prolonging Therapy. J Clin Oncol 2019; 37:2961-2967.
10.09.2019Metastatic Hormone-Sensitive Prostate Cancer: Clinical Decision Making in a Rapidly Evolving Landscape of Life-Prolonging Therapy
10.09.2019J Clin Oncol 2019; 37:2961-2967
VanderWeele David J, Sweeney Christopher J, Petrylak Daniel P, Morgans Alicia K, Higano Celeste S, Gillessen Sommer Silke, Fizazi Karim, Dreicer Robert, Carducci Michael A, Antonarakis Emmanuel S, Hussain Maha
Association Between RECIST Changes and Survival in Patients with Metastatic Castration-resistant Prostate Cancer Receiving Docetaxel
Sonpavde G, Pond G, Templeton A, Fandi A, Tombal B, Rosenthal M, Armstrong A, Petrylak D. Association Between RECIST Changes and Survival in Patients with Metastatic Castration-resistant Prostate Cancer Receiving Docetaxel. Eur Urol 2015
20.10.2015Association Between RECIST Changes and Survival in Patients with Metastatic Castration-resistant Prostate Cancer Receiving Docetaxel
20.10.2015Eur Urol 2015
Sonpavde Guru, Pond Gregory R, Templeton Arnoud, Fandi Abderrahim, Tombal Bertrand, Rosenthal Mark, Armstrong Andrew J, Petrylak Daniel P
Phase II randomized study of figitumumab plus docetaxel and docetaxel alone with crossover for metastatic castration-resistant prostate cancer
de Bono J, Scranton J, Wang T, Hudes G, Gillessen Sommer S, Fong P, Sandhu S, Aparicio L, Saad F, Petrylak D, Pandha H, Piulats J, Pollak M. Phase II randomized study of figitumumab plus docetaxel and docetaxel alone with crossover for metastatic castration-resistant prostate cancer. Clin Cancer Res 2014; 20:1925-34.
17.02.2014Phase II randomized study of figitumumab plus docetaxel and docetaxel alone with crossover for metastatic castration-resistant prostate cancer
17.02.2014Clin Cancer Res 2014; 20:1925-34
de Bono Johann S, Scranton Judith, Wang Tao, Hudes Gary R, Gillessen Sommer Silke, Fong Peter, Sandhu Shahneen K, Aparicio Luis Miguel A, Saad Fred, Petrylak Daniel P, Pandha Hardev S, Piulats Josep M, Pollak Michael N